Lantheus Holding Stock Price, News & Analysis

Lantheus Holdings announced a collaboration with Novartis to include PYLARIFY® (piflufolastat F18) in clinical trials for Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) targeting prostate cancer. This partnership aims to explore how PSMA PET imaging agents can enhance patient access to PSMA-targeted therapies.

The U.S. Total Addressable Market for PSMA PET imaging is now estimated at approximately $1.1 billion, an increase from the previous $220 million, reflecting an additional 30,000 scans per year for metastatic castration-resistant prostate cancer.

Lantheus Holdings (NASDAQ: LNTH) announced that Mary Anne Heino, President and CEO, along with Bob Marshall, CFO, will present at the Barclays Global Healthcare Conference on March 15, 2022, at 8:30 a.m. ET in Miami, FL. Investors can access a live webcast of the presentation through the Investors section on the company’s website, with a replay available for 30 days afterward. Lantheus provides innovative imaging diagnostics and therapeutics, focusing on serious medical conditions.

Lantheus Holdings, a leader in medical imaging and therapeutics, is set to host its inaugural investor day on May 17, 2022, at 8:00 a.m. in New York City. The event, featuring President and CEO Mary Anne Heino, will cover the company’s prostate cancer and microbubble franchises, along with its overall business strategy. Attendees can expect a PYLARIFY panel discussion and Q&A sessions. In-person attendance is limited and registration will be required. A live webcast will also be available for those unable to attend, ensuring broad access to the event's insights.

Lantheus Holdings (NASDAQ: LNTH) has appointed Ms. Minnie Baylor-Henry, Esq., a prominent regulatory affairs expert, to its Board of Directors. Effective immediately, she will also serve on the Compensation and Science and Technology Committees. Following this appointment, the Board will consist of nine directors, with eight being independent. Brian Markison, Chairman of the Board, highlighted her significant industry experience as essential for the company’s strategy to enhance shareholder value and improve patient outcomes.

Lantheus reported strong financial results for Q4 and FY 2021, with worldwide revenue of $129.6 million and $425.2 million, reflecting increases of 37.6% and 25.3% year-over-year, respectively. However, the company faced a GAAP net loss of $40.2 million for Q4 and $71.3 million for the full year. Adjusted fully diluted EPS improved to $0.25 and $0.49 for Q4 and FY 2021, marking increases of 263.5% and 4.0%. The company anticipates Q1 revenue guidance of $160 million - $170 million and FY 2022 guidance of $685 million - $710 million.

Lantheus Holdings has received FDA approval for its on-site drug manufacturing facility in North Billerica, Massachusetts, designed to produce DEFINITY® (Perflutren Lipid Microsphere), a leading ultrasound enhancing agent. This 16,000 sq. ft. facility aims to enhance supply security and support future growth. The facility will aid in margin expansion as DEFINITY supply becomes integrated from this location. The company intends to ship DEFINITY from this facility immediately, marking an important step in ensuring adequate supply for patients with suboptimal echocardiograms.

Lantheus Holdings, Inc. (NASDAQ: LNTH) announced that data from the OSPREY pivotal trial will be presented at the 2022 ASCO GU Meeting on February 17, 2022, in San Francisco, CA. The presentation will cover the performance of Piflufolastat F 18-PET/CT in prostate cancer patients, specifically analyzing standardized uptake value results based on PSA and Gleason scores. PYLARIFY is highlighted as a PSMA-targeted PET imaging agent for identifying recurrent and metastatic prostate cancer. This data presentation is a key opportunity to showcase Lantheus's advancements in oncology diagnostics.

Lantheus Holdings (NASDAQ: LNTH) has scheduled a conference call to announce its financial and operational results for the fourth quarter and full year of 2021. This event will take place on February 24, 2022, at 8:00 a.m. ET. Investors can join via telephone or through a live webcast on the company's website. Following the call, a replay will be accessible for 30 days. Lantheus is known for its diverse portfolio of imaging diagnostics and therapeutics, aimed at addressing serious medical conditions.

Lantheus (NASDAQ: LNTH) announced a collaboration between its subsidiary EXINI Diagnostics and the Prostate Cancer Clinical Trials Consortium (PCCTC) to enhance AI-enabled imaging biomarkers for prostate cancer. The partnership aims to integrate Lantheus' FDA-cleared AI platform into early-phase studies, improving patient selection and therapy response assessments. This initiative involves Lantheus' PSMA PET/CT and bone scintigraphy imaging technologies. Prostate cancer is the second most common cancer among men, with an estimated 268,500 new cases in 2022 in the U.S.